Copy
Problems viewing this newsletter? View it in your browser >



May 14, 2014

Dear Advocate,

Earlier today, the US Centers for Disease Control (CDC) and the US Public Health Service released new clinical guidelines on using daily oral TDF/FTC (also known as Truvada) as PrEP for HIV prevention.

This type of guideline is used by the US government to set national norms for health providers. It is the first such national guideline issued anywhere for PrEP use. It provides clear instructions for health providers about providing TDF/FTC as PrEP for individuals at “substantial risk for HIV infection”. This is a significant step to making this PrEP strategy a well-understood and accessible option for men and women living in the United States. Ideally other countries and global agencies will replicate this important step. AVAC is hosting a webinar on Tuesday, May 20 at 10am ET where representatives of the CDC will discuss these guidelines.

Register for the webinar here.

The new guidelines replace CDC’s prior interim guidance documents, and come two years after the US Food and Drug Administration approved daily TDF/FTC for use in HIV prevention. The guidelines explain the evidence for PrEP to date and give step-by-step instructions for doctors and other health providers about how to safely prescribe and monitor PrEP for people with different risk factors for HIV infection. There is also a section on “financial case-management issues” to help providers address barriers to access. The main guidelines were published alongside a providers’ supplement with additional materials and tools for clinicians who prescribe PrEP.

The guidelines are an important reference tool for advocates and individuals seeking PrEP, since they lay out the arguments and evidence for a strategy that is still unfamiliar or relatively unknown to some providers.

Even as the guidelines create an environment for more widespread PrEP use, there is still a need to do “implementation science” to find out how best to deliver TDF/FTC as PrEP. One way to do this is through demonstration and implementation projects that evaluate different approaches to PrEP service delivery. CDC is supporting this work as well—however additional studies are needed to answer the full range of questions for men and women in the US and globally.

Also, on Tuesday, May 20 at 1pm ET the CDC will host Public Health Grand Rounds on PrEP, which will be live webcast and archived after the event. Click here for details.

For more information on PrEP research, ongoing implementation projects, access, guidance and more, visit www.prepwatch.org, and questions or comments are welcome, as always!

Best,
AVAC


Forward This IssueDo you know someone who might be interested in receiving this newsletter?
Forward > 


Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
Unsubscribe > 


Contact Us T: +1 212 796 6423
E: avac@avac.org

W: www.avac.org